Ascendis Pharma (ASND) news
Recent news
Biomarin: For product includes NavePegritede, Yuviwel
BioMarin Pharmaceutical Inc. has entered into a licensing agreement with Ascendis Pharma, granting the latter a non-exclusive, worldwide license to use navepegritide, an active ingredient in Ascendis’ recently approved achondroplasia treatment, Yuviwel. Under the terms of the agreement, BioMarin…
AInvest Wire · Sep 30, 2026Ascendis Pharma A/S - All licenses in metabolic and cardiovascular diseases to revert to Ascendis; no continuing financial obligations
AInvest Wire · Sep 14, 2026Ascendis Pharma A/S - To regain exclusive rights to transccon technology in metabolic and cardiovascular diseases
Ascendis Pharma A/S has entered into a strategic collaboration and licensing agreement with Novo Nordisk A/S, granting the latter exclusive worldwide license to its TransCon technology platform for the development and commercialization of products in metabolic and cardiovascular diseases. The…
AInvest Wire · Sep 14, 2026Ascendis announces planned $400 million share repurchase program
AInvest Wire · Sep 14, 2026Ascendis Pharma A/S: Oppenheimer raises target price to $312 from $304
Oppenheimer has raised its price target for Ascendis Pharma A/S (NASDAQ:ASND) to $312 from $304, while maintaining an Outperform rating, following settlement with BioMarin Pharmaceutical . The settlement, announced on June 13, resolves all litigation and grants Ascendis a non-exclusive, global…
AInvest Wire · Sep 2, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.